DICORNAI pigmentosa, and, moreover, on pharmacological grounds it would be unlikely for aspirin, an acid substance, to have such an action, as most recognized histamine liberators are bases.
Another possibility would be that aspirin was acting as a hapten, forming an antigen when combined with serum proteins. We have no clear evidence against this, but we would have to assume that at least one in five patients who suffered from chronic urticaria would also have such an allergy to aspirin.
That aspirin in some way renders the skin in these patients more sensitive to histamine is suggested by the present report that intradermal histamine weals were larger after aspirin in these patients. In this connexion it is interesting that Juhlin and Rune (1962) have reported that the threshold to 48/80, a known histamine liberator, is lowered in acute urticaria.
It has been stated in the past that aspirin sensitivity is specific to acetylsalicylic acid and does not extend to related compounds. In the present investigations similar reactions were obtained in most patients from sodium salicylatt and phenyl salicylate, and it would seem likely that it is the salicylic acid radical which is responsible for aspirin reactivity.
Whatever the underlying cause, it is now established that a point of great practical importance in the management of patients with urticaria is to avoid any administration of salicylates.
The investigation of a patient with chronic urticaria, aspirin reactivity, and jaundice revealed abnormal liver histology described as atypical portal cirrhosis. This finding prompted the investigation of all patients who reacted to aspirin. To date, two other similar cases have been found. It is intended to report later the details of these three cases with the triad of chronic urticaria, aspirin reactivity, and liver disease. Summary Aspirin-containing drugs will cause exacerbation in some patients with chronic urticaria. In 112 out of 228 patients with chronic urticaria such a reaction could not be excluded from the history, and provocative test doses of aspirin were given ; 50 patients (22%) developed a well-marked increase in the urticaria. No clinical differences could be observed between the patients who reacted in this way and those who did not.
This action of aspirin is probably due to the salicylic acid radical, as most patients tested have had similar reactions with doses of sodium salicylate and phenyl salicylate.
It has been shown in eight patients that the increase in wealing is proportional to the dose of aspirin administered. In four patients who did not react at all to 300 mg. of aspirin there were successively more severe reactions to 600 and 1,200 mg. In four others the reaction increased so much between 300 and 600 mg. that a larger dose was not given. The (Adams and Cobb, 1963 (Bywaters, 1963 
Material and Methods
Each trial was in the form of a double-blind cross-over comparison. The results were expressed sequentially, preference being based on alteration of joint size during the two periods.
All patients had classical or definite rheumatoid arthritis (American Rheumatism Association, 1959) of at least one year's duration. They were selected from consecutive attenders at the rheumatism clinic provided that they had synovitis of the small joints of the hands and that there was no history of intolerance to the relevant drugs. Only those patients were included in whom it was possible to stop all treatment for 14 days before the trial.
In trial 1 prednisone 7.5 mg. daily was compared with placebo, both being administered as a single evening dose. In trial 2 paracetamol 6 g. daily was compared with placebo; each was administered as three tablets four times daily. In trial 3 high dosage of salicylate was given at 5.3 g. (80 gr.) daily in four equal doses and low dosage at 2.6 g. (40 gr.) daily. In trial 4 low dosage of salicylate, 2.6 g. daily, was compared with placebo.
Each drug was given for seven consecutive days, each trial lasting 14 days. All tablets were taken after food. Salicylate was given in its glycinated form as a single tablet containing 660 mg. (10 gr.). After each treatment period the bottles were collected and the number of tablets remaining was checked.
Patients were interviewed a minimum of four times at weekly intervals in each trial. At the first visit joint size and grip strength were measured. These indices were measured again at the second visit. If the difference in joint size was less than 4 mm. and the overall change of grip strength less than 50 mm. Hg they were regarded as having a stable baseline and the trial was started. In those with greater changes further baseline assessment was made until the indices became stable. At the third visit-the end of the first seven-day trial periodthe indices were measured and side-effects recorded, direct questions being avoided. The same programme was followed at the fourth visit, which marked the end of the trial, and the individual preference for either of the treatment periods was noted.
Joint size was measured as the circumference of the proximal interphalangeal joints of the four fingers of each hand, and the distal interphalangeal joint of each thumb-that is, the sum of the circumference measurements of the 10 digits. It was measured by a gauge (Fig. 1 arthritis twice at an interval of an hour. The average difference between the two readings was 3.0 mm. For three observers without previous experience of the method, under similar conditions, the mean difference was 4.5 mm. All patients were seen at the same time of day. In a group of eight patients in hospital with active rheumatoid arthritis there was an apparent decrease of joint size throughout the day (Fig. 3) . The grip strength was greater in the evening than in the morning, the usual diurnal pattern (Wright, 1959 ), but the difference was not statistically significant. To express the results sequentially it is necessary to define a significant difference of joint size. In 50 outpatients with rheumatoid arthritis joint size was measured twice at an interval of seven days (Table II) . The readings at the beginning and end of the week differed by 3 mm. or less in 42 (84%) of the patients. The mean difference was 2.12 mm. (S.D. 1.4). In eight patients (16%) the difference was 4 mm. or greater. A difference of 4 mm. was therefore arbitrarily assumed to be significant over a seven-day period. (Fig. 4) . As there was a difference of less than 4 mm. of joint size in two patients, the total number involved in the trial was 13. There was a significant increase in grip strength on prednisone compared with placebo in those patients in whom there was reduction of swelling. The mean grip strength on prednisone was 379 mm. Hg and on placebo 292 mm. Hg (t=2.3; n=20; 0.05>P>0.02). The preference was for prednisone in 8 of the 11 patients, 1 preferred placebo, and 2 found no difference.
Trial 2: Paracetamol v. Placebo.-There was no significant difference of joint size in patients on paracetamol compared with placebo (Fig. 5) . Of the 14 fulfilling the criteria for inclusion in the sequential analysis seven had less swelling on paracetamol and seven on placebo. Four patients were excluded from this trial because they had inadequate alteration of joint size. 
Side-effects
In trial 1 two out of 13 patients had subjective reactions on prednisone.
In trial 2 side-effects occurred in 10 out of 18 on paracetamol -generally dyspepsia and drowsiness-compared with three on placebo, all of which were dyspepsia. High dosage of salicylate (trial 3) was associated with sideeffects in six out of 18 patients, the complaint being tinnitus in four and nausea in two. On low dosage giddiness and abdominal distension were each noted once.
In trial 4 four out of 15 had complaints on low dosage of salicylate. These were frequency of micturition (1), giddiness (1), and dyspepsia (2). Placebo was associated with side-effects in three patients, two complaining of depression and one of a hot feeling.
Discussion
Trial 1 illustrates the effect of a known anti-inflammatory agent. Significant reduction of joint swelling is -associated with improvement of grip strength and preference for prednisone.
Trial 2 defines the pattern that is obtained from a known analgesic agent without anti-inflammatory action: There is no difference of joint size on paracetamol compared with placebo. Both grip strength and preference suggest that there is some benefit from paracetamol compared with placebo, though neither alters to a statistically significant extent.
These findings suggest that under certain conditions alteration of joint size may be related specifically to reduction of inflammation. Grip strength and preference are less specific indices in that they may also improve after the administration of analgesic agents.
In trial 3 high dosage of salicylate is associated with reduction of joint size when compared with low dosage. The preference is strongly in favour of high dosage. The mean grip strength is better on high dosage, though the change does not reach significant levels.
There is no difference of joint size on low dosage of salicylate compared with placebo, a point shown in trial 4. There is no difference of preference: the grip strength is better on placebo but not to a significant extent.
A possible disadvantage of sequential analysis is the introduction of selection, because experiments in which there is no significant difference are discarded. In our study this is accepted deliberately to exclude the patient who lacks reversible soft-tissue inflammatory swelling. The alteration of joint size that follows the administration of an anti-inflammatory agent is relatively small. It is impossible to determine beforehand which patients possess only irreversible joint swelling. The (Hart and Boardman, 1963) . In the presence of a limited amount of inflammatory swelling it is possible that any factor promoting improvement is associated with reduction of joint size, provided the period of administration is long enough.
In these circumstances differences may be demonstrated more clearly by comparing the rate of change during a limited period.
The use of a cross-over trial may be criticized, because subjects starting on an active agent may have less chance of responding It is suggested that the plan of this trial provides a simple method for the clinical assessment of the anti-inflammatory properties of a rapidly acting drug.
Though many drugs have been used in thc symptomatic treatment of angina pectoris almost the only one which has been consistently shown to be of benefit in relieving the myocardial ischaemia is glyceryl trinitrate. In a previous study it was shown to be of considerable value when used prophylactically, but no better than a placebo when given after an attack of anginal pain had developed (Sandler et al., 1963) . It has been suggested that this lack of effect of gylceryl trinitrate in relieving established anginal pain might be due to the time it took to dissolve in the mouth (Evans, 1963) , so that by then the angina had improved spontaneously. In relation to this possibility the development of an aerosol preparation of glyceryl trinitrate seemed of considerable interest, since such a preparation would be rapidly absorbed in the lungs with more rapid arrival in the myocardium. Preliminary observations (G. G. Gensini, unpublished; A. Black, unpublished) suggested that glyceryl trinitrate aerosol was of value in treating angina, and it was therefore decided to undertake an objective evaluation of the aerosol preparation (Cardamist) in treating angina pectoris and to compare it with the standard tablet trinitrate preparation.
Patients and Methods
Twenty-three patients with well-authenticated and typical attacks of angina pectoris were studied. These subjects, aged from 39 to 69 years, comprised 20 men and 3 women. In all of them the angina had settled down to a stable pattern, and the duration ranged from 3 to 72 months, with attacks occurring from 3 to 40 times weekly. The presumptive cause of the angina was coronary artery disease in all 23, but only four had evidence of previous myocardial infarction. All the patients were admitted to hospital for a period of six days for the trial, and a daily exercise tolerance was carried out in each of them. The type of test has been described in detail in an earlier publication (Sandler, 1961) , and is based on a modification of the Master two-step test, the patient exercising over two steps, each 9 in. (23 cm.) high, until he develops angina or completes 100 circuits over the steps ; the test is stopped immediately if significant ischaemic change appears in the electrocardiogram during exercise. In addition to conventional electrocardiography, recording chest lead V5 before and after exercise, the patient is monitored continuously during exercise by means of a radiocardiograph. By this means ischaemic change can be detected immediately, even if unaccompanied by anginal pain, and the exercise terminated (Sandler, 1967) . Depression of the ST segment of plane or sagging contour lasting at least 0.08 second, in either the radiocardiogram or the V5, was taken as evidence of myocardial ischaemia (Lloyd-Thomas, 1961 ; Master and Rosenfeld, 1961; Bellet et al., 1962) . Junctional depression, when it occurred, was accepted as significant of ischaemia only when the QX/QT ratio exceeded 50% (Master and Rosenfeld, 1961) .
The preparations studied were glyoeryl trinitrate aerosol delivering 0.13 mg. of the drug per inhalation-the dose investigated being 0.26 mg. (two inhalations)-an identical placebo aerosol, and standard tablets of 0.5 mg. of glyceryl trinitrate. Study of the aerosol preparations was made on a double-blind basis, and the distribution of active and placebo preparations in each pair of aerosols was randomized. It was not thought necessary to include a placebo tablet with the glyceryl trinitrate tablet, since a previous double-blind study had confirmed the effectiveness of the latter in this type of trial (Sandler et al., 1963) . Each of the three preparationsglyceryl trinitrate aerosol, placebo aerosol, and glyceryl trinitrate tablet-was assessed when given both before exercise was
